Filing Flows › Cartesian Therapeutics (RNAC) › Q4 2025 › vs Q3 2025
Cartesian Therapeutics (RNAC) Q4 2025 vs Q3 2025 (quarter over quarter)
Cartesian Therapeutics's revenue rose $495K (+110%) from $452K in Q3 2025 to $947K in Q4 2025.
Cartesian Therapeutics, Q4 2025: revenue $947K, net loss $92.6M, operating cash flow −$17.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $947K | $452K | $495K | +110% |
| Net loss | $92.6M | $35.9M | $56.7M | +158% |
| Costs & expenses | $93.5M | $36.4M | $57.2M | +157% |
| Operating costs | $79.6M | $21.5M | $58.1M | +270% |
| Interest & other, net | $13.9M | $14.8M | −$899K | -6% |
| Research & development | $14.7M | $13.8M | $887K | +6% |
| General & admin | $8.2M | $7.7M | $481K | +6% |
| Operating cash sources | $92.6M | $35.9M | $56.7M | +158% |
| Depreciation | $600K | $600K | $0 | 0% |
| Share-based compensation | $2.1M | $2.6M | −$446K | -17% |
| Working capital & other | $72.1M | $17.1M | $55.0M | +321% |
| Cash used in operations | $17.7M | $15.6M | $2.1M | +14% |
| Net loss absorbed | $92.6M | $35.9M | $56.7M | +158% |
Questions
How much did Cartesian Therapeutics's revenue grow quarter over quarter in Q4 2025?
Cartesian Therapeutics's revenue rose $495K (+110%) from $452K in Q3 2025 to $947K in Q4 2025.